Biogen shakeup could shift Alzheimer's research
AxiosMAR 25 2022
Although the withdrawal of Aduhelm is a disappointment, Biogen is looking ahead to major reforms and a new and promising monoclonal antibody called Lecanemab. Between a stunning strategic overhaul in the company, and the rapid acceleration of Lecanemab towards regulation approval, Biogen is progressing towards its ultimate goal of finding an effective Alzheimer's treatment.
The controversy surrounding Aduhelm is a colossal failure that has cost Biogen's CEO his job. The FDA approved the drug despite unanimous opposition from its advisory panel. When evidence showed it was ineffective, Biogen selected the most convenient data to plead the case for the treatment. The company has destroyed itself with corrupt and underhand tactics.